What happened
FDA’s Guidances | Drugs page explains that guidance documents reflect the Agency’s current thinking on particular subjects, do not create or confer rights, and do not bind FDA or the public. It states that alternative approaches may be used when they satisfy applicable statutory or regulatory requirements. The page directs users to FDA’s guidance search, including filtering by the Center for Drug Evaluation and Research and other criteria. It lists drug-related categories such as Chemistry, Manufacturing, and Controls, Current Good Manufacturing Practice, ICH-Quality, Microbiology, Pharmaceutical Quality, Compliance, and Electronic Submissions. It also links to withdrawn guidances, the CDER Guidance Agenda, product-specific guidances, Spanish translations, and good guidance practices resources.
Why it matters
For pharmaceutical manufacturers, the page provides access to FDA materials relevant to CGMP, CMC, pharmaceutical quality, microbiology, compliance, and electronic submissions. Its description of guidance status may matter when evaluating FDA recommendations: guidance expresses current thinking but is nonbinding, and alternative approaches may be used if applicable legal requirements are satisfied. Links to withdrawn guidances and the CDER agenda may also support awareness of the guidance landscape.
Key topics: FDA drug guidance search and access, Nonbinding status of FDA guidance documents, CDER guidance topics and agenda